Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
Back to dashboard
Company Information
About this company
Key people
Peter Harwin
Independent Non-Executive Chairman of the Board
Alexandra Balcom
Independent Director
David Charles Lubner
Independent Director
Susan M. Moran
Independent Director
Jonathan McNeill
President, Chief Operating Officer
Joshua Brumm
Chief Executive Officer, Director
Richard Scalzo
Chief Financial Officer
Ryan Lynch
Senior Vice President - Finance, Chief Accounting Officer, Treasurer
Jan Pinkas
Chief Scientific Officer
Barbara Bispham Hale
General Counsel, Corporate Secretary
Ellie Eunkyung Im
Chief Medical Officer
Jonathan Violin
Director
Click to see more
Key facts
- Shares in issue35.67m
- EPICCBIO
- ISINKYG2545C1042
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$581.37m
- Employees44
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.